ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

Slides:

Advertisements

Similar presentations

Enhanced ILC2 expansion after depletion of NK cells during the early stage of allergic and fibrotic lung inflammation. Enhanced ILC2 expansion after depletion.

Advertisements

Synergistic antitumor effect of anti-CD40/CpG and 14

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

Vascular HR ligand expression depends on tumor anatomical location.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Volume 26, Issue 4, Pages (April 2018)

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Exosome-mediated inhibition of T cells is reversible.

L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

coTCRcys-transduced T cells control tumor growth in vivo.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78.

Matriptase-2 inhibited breast tumor development in vivo.

Depletion of UCP1 and Myf5 population reduced xenograft growth.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

5FU-induced specific activation of CD8+ T cells.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.

Uptake of TEX by DCs in vivo.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.

Canonical but not adaptive NK-cell function is suppressed by Tregs.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Neutralization of CSF1 and Ad5-HRG treatment.

Effect of nivolumab or ipilimumab on immune responses to vaccination in cynomolgus monkeys. Effect of nivolumab or ipilimumab on immune responses to vaccination.

Characterization of DNA-PK and PARP-1 levels and activities in the cell lines studied. Characterization of DNA-PK and PARP-1 levels and activities in the.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

PK profile of OTL78. PK profile of OTL78. A, Representative time-dependent whole-body fluorescence images over white light images of a mouse bearing 22Rv1.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

ADU-S100 primes the innate immune system in tolerant, tumor bearing neu/N mice. ADU-S100 primes the innate immune system in tolerant, tumor bearing neu/N.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

MPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. mPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. Cell-to-cell.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo. Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo.

MDSC population in patient peripheral blood.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Phenotyping of T cells. Phenotyping of T cells. Circulating lymphocytes from a tumor-naïve C57BL/6 mice (left column) were compared with those from C57BL/6.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

Presentation transcript:

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. Tumor-bearing FVB/N mice were depleted of CD4+, CD8+, both CD4+ and CD8+ T cells, and NK cells using biweekly intraperitoneal injections of 250 μg of anti-CD4 (clone GK1.1), anti-CD8 (clone 2.43), or both anti-CD4 and CD8, and anti-NK1.1 (clone PK136). Injection of depleting antibodies began 1 week prior to tumor implantation and depletion efficacy was confirmed by flow cytometry (>90% depletion). Tumor growth (A) and survival (B) after CD4+ T-cell depletion, CD8+ T-cell depletion, CD4+ and CD8+ T-cell depletion, and NK cell depletion (C and D) were measured at the indicated time points. All data are representative of three independent experiments with 5 mice/group. *, P < 0.05; ****, P < 0.0001. Jeremy B. Foote et al. Cancer Immunol Res 2017;5:468-479 ©2017 by American Association for Cancer Research